ArticleFrontiers in oncology2026
Identification of a nuclear transcriptional module associated with ERα and E2F/FOXM1 signaling across PAM50 breast cancer subtypes.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is the most prevalent and lethal cancer among women worldwide. Although classification based on ERα, PR, and HER2 status guides treatment decisions, misclassification remains a challenge due to the complexity of ERα-associated transcriptional network. Identifying biomarkers that better reflect ERα activity may improve tumor stratification and therapeutic decision-making. We hypothesized that an ERα-related transcriptional framework could improve molecular characterization of breast cancer subtypes. Methods: Clinicopathological features were evaluated in relation to PAM50 subtypes. Gene expression profiles from fresh breast tumor biopsies (n=65) were analyzed and integrated with ERα-related genes identified through literature review and pathway databases (KEGG, WikiPathways, Reactome, and IPA). Differentially expressed genes among subtypes were used to construct a nuclear module for functional enrichment and protein interaction analyses. Selected genes were evaluated by RT-qPCR in breast cancer cell lines. The reproducibility of the module expression was assessed in the independent public cohort GSE18229. Correlation analyses were performed to evaluate associations between module genes and Results: Menopausal status showed a significant association with PAM50 subtypes. Among 647 ERα-related genes, a 34-gene nuclear module was identified as a highly interconnected network. Genes enriched in LumB, HER2-enriched, and basal and downregulated in LumA and normal-like subtypes were mainly associated with proliferation and cell cycle regulation ( Conclusion: This 34-gene module represents an interconnected transcriptional program enriched in E2F/FOXM1 signaling and ERα-associated processes. The integrated analysis of genes involved in hormone signaling, proliferation, genome regulation, and cancer-related processes may reveal subtype-specific expression patterns reflecting ERα activity. We propose the 34-gene panel as a candidate transcriptional framework that may provide insights into BC subtype-discrimination. Further validation in larger cohorts and additional experimental validation are required to determine its potential utility as a biomarker signature for breast cancer stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.